Labeler
E.R. Squibb & Sons, L.L.C. NDC Codes
E.R. Squibb & Sons, L.L.C. lists 51 finished drug products in the FDA NDC Directory under NDC labeler code 0003.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Sprycel, Cobenfy, Opdivo, Orencia, Eliquis, Reyataz, Baraclude, Zenbexus, Opdivo Qvantig, Augtyro, ELIQUIS 30-Day Starter Pack, Empliciti, Yervoy, Azactam, Eliquis Sprinkle
- Active ingredients
- Nivolumab, Dasatinib, Apixaban, Atazanavir sulfate, Abatacept, Xanomeline, Trospium chloride, Triamcinolone acetonide, Entecavir, Iberdomide hydrochloride, Hyaluronidase (Human recombinant), Repotrectinib
- NDC labeler codes
- 0003
- Strengths
- Nivolumab 10 mg/mL; Nivolumab 120 mg/mL; Hyaluronidase (Human recombinant) 2000 U/mL; Trospium chloride 20 mg/1; Atazanavir sulfate 300 mg/1; Ipilimumab 5 mg/mL; Iberdomide hydrochloride .75 mg/1; Iberdomide hydrochloride 1 mg/1; Apixaban .15 mg/1; Apixaban .5 mg/1; Repotrectinib 160 mg/1; Xanomeline 50 mg/1; Xanomeline 125 mg/1; Trospium chloride 30 mg/1; Xanomeline 100 mg/1; Repotrectinib 40 mg/1; Deucravacitinib 6 mg/1; Nivolumab 12 mg/mL; Relatlimab 4 mg/mL; Triamcinolone acetonide 80 mg/mL
- Dosage forms
- Injection, Tablet, Capsule, Injection, Solution, Tablet, Film coated, Kit, Injection, Powder, Lyophilized, For solution, Capsule, Coated pellets, Injection, Suspension, Injection, Powder, For solution, Solution, Capsule, Gelatin coated, Tablet, For suspension, Powder
- Routes
- Oral, Intravenous, Subcutaneous, Intramuscular, Intra-articular, Intralesional, Topical
- Drug classes (FDA established)
- Kinase Inhibitor, Programmed Death Receptor-1 Blocking Antibody, Factor Xa Inhibitor, Corticosteroid, Protease Inhibitor, Selective T Cell Costimulation Modulator, Cholinergic Muscarinic Agonist, Cholinergic Muscarinic Antagonist, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Endoglycosidase, SLAMF7-directed Immunostimulatory Antibody, CTLA-4-directed Blocking Antibody, Monobactam Antibacterial, Tyrosine Kinase 2 Inhibitor, Lymphocyte Activation Gene-3 Blocker, Cytochrome P450 3A Inhibitor, Selective T Cell Costimulation Blocker
- HCPCS / J-code
- J9299 — Injection, nivolumab, 1 mg
- Package NDCs
- 73
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Zenbexusiberdomide | Iberdomide hydrochloride .75 mg/1 | CapsuleOral | 0003-5700 | 00003-5700-21 | — |
| Zenbexusiberdomide | Iberdomide hydrochloride 1 mg/1 | CapsuleOral | 0003-5710 | 00003-5710-21 | — |
| Eliquis Sprinkleapixaban | Apixaban .15 mg/1 | CapsuleOral | 0003-0898 | 00003-0898-28 | — |
| Eliquisapixaban | Apixaban .5 mg/1 | Tablet, For suspensionOral | 0003-1028 | 00003-1028-1200003-1028-2800003-1028-84 | — |
| Opdivo Qvantignivolumab and hyaluronidase-nvhy | Nivolumab 120 mg/mL; Hyaluronidase (Human recombinant) 2000 U/mL | Injection, SolutionSubcutaneous | 0003-6120 | 00003-6120-01 | — |
| Opdivo Qvantignivolumab and hyaluronidase-nvhy | Nivolumab 120 mg/mL; Hyaluronidase (Human recombinant) 2000 U/mL | Injection, SolutionSubcutaneous | 0003-3120 | 00003-3120-01 | — |
| Augtyrorepotrectinib | Repotrectinib 160 mg/1 | CapsuleOral | 0003-4160 | 00003-4160-1400003-4160-60 | — |
| Cobenfyxanomeline and trospium chloride | Xanomeline 50 mg/1; Trospium chloride 20 mg/1 | Capsule, Coated pelletsOral | 0003-0050 | 00003-0050-1400003-0050-6000003-0050-98 | — |
| Cobenfyxanomeline and trospium chloride | Xanomeline 125 mg/1; Trospium chloride 30 mg/1 | Capsule, Coated pelletsOral | 0003-0125 | 00003-0125-1400003-0125-6000003-0125-98 | — |
| Cobenfyxanomeline and trospium chloride | Xanomeline 100 mg/1; Trospium chloride 20 mg/1 | Capsule, Coated pelletsOral | 0003-1100 | 00003-1100-1400003-1100-6000003-1100-98 | — |
| Cobenfyxanomeline and trospium chloride | — | Kit | 0003-5150 | 00003-5150-14 | — |
| Cobenfyxanomeline and trospium chloride | — | Kit | 0003-5200 | 00003-5200-56 | — |
| Augtyrorepotrectinib | Repotrectinib 40 mg/1 | CapsuleOral | 0003-4040 | 00003-4040-1200003-4040-60 | — |
| Sotyktudeucravacitinib | Deucravacitinib 6 mg/1 | Tablet, Film coatedOral | 0003-0895 | 00003-0895-1100003-0895-91 | — |
| Opdualagnivolumab and relatlimab-rmbw | Nivolumab 12 mg/mL; Relatlimab 4 mg/mL | InjectionIntravenous | 0003-7125 | 00003-7125-11 | — |
| Opdivonivolumab | Nivolumab 10 mg/mL | InjectionIntravenous | 0003-3756 | 00003-3756-14 | J9299 |
| Kenalog-80triamcinolone acetonide | Triamcinolone acetonide 80 mg/mL | Injection, SuspensionIntra-articular, Intramuscular | 0003-0315 | 00003-0315-0500003-0315-20 | — |
| Opdivonivolumab | Nivolumab 10 mg/mL | InjectionIntravenous | 0003-3734 | 00003-3734-13 | J9299 |
| ELIQUIS 30-Day Starter Packapixaban | — | Kit | 0003-3764 | 00003-3764-74 | — |
| ELIQUIS 30-Day Starter Packapixaban | — | Kit | 0003-3765 | — | — |
| Emplicitielotuzumab | Elotuzumab 300 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous | 0003-2291 | 00003-2291-11 | — |
| Emplicitielotuzumab | Elotuzumab 400 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous | 0003-4522 | 00003-4522-11 | — |
| Evotazatazanavir and cobicistat | Atazanavir sulfate 300 mg/1; Cobicistat 150 mg/1 | TabletOral | 0003-3641 | 00003-3641-11 | — |
| Opdivonivolumab | Nivolumab 10 mg/mL | InjectionIntravenous | 0003-3772 | 00003-3772-11 | J9299 |
| Opdivonivolumab | Nivolumab 10 mg/mL | InjectionIntravenous | 0003-3774 | 00003-3774-12 | J9299 |
| Reyatazatazanavir | Atazanavir sulfate 50 mg/1 | PowderOral | 0003-3638 | 00003-3638-10 | — |
| Eliquisapixaban | Apixaban 2.5 mg/1 | Tablet, Film coatedOral | 0003-0893 | 00003-0893-2100003-0893-3100003-0893-91 | — |
| Eliquisapixaban | Apixaban 5 mg/1 | Tablet, Film coatedOral | 0003-0894 | 00003-0894-2100003-0894-3100003-0894-70+1 more | — |
| Orenciaabatacept | Abatacept 125 mg/mL | Injection, SolutionSubcutaneous | 0003-2188 | 00003-2188-1100003-2188-5100003-2188-90+1 more | — |
| Orenciaabatacept | Abatacept 50 mg/.4mL | Injection, SolutionSubcutaneous | 0003-2814 | 00003-2814-11 | — |
| Orenciaabatacept | Abatacept 87.5 mg/.7mL | Injection, SolutionSubcutaneous | 0003-2818 | 00003-2818-11 | — |
| Nulojixbelatacept | Belatacept 250 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous | 0003-0371 | 00003-0371-13 | — |
| Yervoyipilimumab | Ipilimumab 5 mg/mL | InjectionIntravenous | 0003-2327 | 00003-2327-11 | — |
| Yervoyipilimumab | Ipilimumab 5 mg/mL | InjectionIntravenous | 0003-2328 | 00003-2328-22 | — |
| Spryceldasatinib | Dasatinib 80 mg/1 | TabletOral | 0003-0855 | 00003-0855-22 | — |
| Spryceldasatinib | Dasatinib 140 mg/1 | TabletOral | 0003-0857 | 00003-0857-22 | — |
| Azactamaztreonam | Aztreonam 1 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | 0003-2560 | 00003-2560-16 | — |
| Azactamaztreonam | Aztreonam 2 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | 0003-2570 | 00003-2570-16 | — |
| Kenalog-40triamcinolone acetonide | Triamcinolone acetonide 40 mg/mL | Injection, SuspensionIntra-articular, Intramuscular | 0003-0293 | 00003-0293-0500003-0293-2000003-0293-28 | — |
| Kenalog-10triamcinolone acetonide | Triamcinolone acetonide 10 mg/mL | Injection, SuspensionIntra-articular, Intralesional | 0003-0494 | 00003-0494-20 | — |
| Haloghalcinonide | Halcinonide 1 mg/mL | SolutionTopical | 0003-0249 | 00003-0249-1500003-0249-20 | — |
| Orenciaabatacept | Abatacept 250 mg/15mL | Injection, Powder, Lyophilized, For solutionIntravenous | 0003-2187 | 00003-2187-13 | — |
| Spryceldasatinib | Dasatinib 100 mg/1 | TabletOral | 0003-0852 | 00003-0852-22 | — |
| Spryceldasatinib | Dasatinib 70 mg/1 | TabletOral | 0003-0524 | 00003-0524-11 | — |
| Spryceldasatinib | Dasatinib 20 mg/1 | TabletOral | 0003-0527 | 00003-0527-11 | — |
| Spryceldasatinib | Dasatinib 50 mg/1 | TabletOral | 0003-0528 | 00003-0528-11 | — |
| Baracludeentecavir | Entecavir .5 mg/1 | Tablet, Film coatedOral | 0003-1611 | 00003-1611-12 | — |
| Baracludeentecavir | Entecavir 1 mg/1 | Tablet, Film coatedOral | 0003-1612 | 00003-1612-12 | — |
| Baracludeentecavir | Entecavir .05 mg/mL | SolutionOral | 0003-1614 | 00003-1614-12 | — |
| Reyatazatazanavir | Atazanavir sulfate 300 mg/1 | Capsule, Gelatin coatedOral | 0003-3622 | 00003-3622-12 | — |
E.R. Squibb & Sons, L.L.C.: common questions
- What is E.R. Squibb & Sons, L.L.C.'s NDC labeler code?
- 0003. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for E.R. Squibb & Sons, L.L.C.?
- Med-Code's HCPCS directory matches J9299 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.